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Highlights 
 •The first report on the efficacy of the Mn complex [Mn(CO)3(tpa-κ3N)]Br against 
Streptococcus pneumonia. 
 •The [Mn(CO)3(tpa-κ3N)]Br alone showed moderate in vitro efficacy against S. 
pneumoniae coupled with bactericidal activity. 
 •The [Mn(CO)3(tpa-κ3N)]Br in combination with traditional antibiotics have potential 
as antimicrobial and resistance breaker against multidrug-resistant S. pneumoniae. 
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Objectives: The emergence of multidrug-resistance (MDR) in Streptococcus pneumoniae 
clones and non-vaccine serotypes necessitate the development of novel treatment strategies. 
This work aimed to determine the efficacy of the Mn complex [Mn(CO)3(tpa-κ3N)]Br against 
clinically important MDR strains of S. pneumoniae. 
Methods: Twenty MDR clinical S. pneumoniae strains were included in this study. Minimum 
inhibitory concentrations (MICs) of [Mn(CO)3(tpa-κ3N)]Br were determined via broth 
microdilution alone and in combination with other antimicrobial agents using checkerboard 
assays and/or disc diffusion tests. In vitro efficacy was assessed by time-kill assays while in 
vivo efficacy was tested using the insect model Galleria mellonella.  
Results: [Mn(CO)3(tpa-κ3N)]Br showed moderate in vitro efficacy against S. pneumoniae 
coupled with bactericidal activity. Checkerboard and disc diffusion assays showed synergy 
between [Mn(CO)3(tpa-κ3N)]Br and tetracycline, and the combination of both agents caused 
rapid kill-kinetics and reduced the MIC below the susceptibility breakpoint of 1 mg/L even 
for tetracycline-resistant strains of S. pneumoniae. Similar results were observed for the 
erythromycin- and the co-trimoxazole-Mn complex combination. In the G. mellonella 
infection model, mortality and morbidity rates at 96 h were significantly lower in larvae 
treated with [Mn(CO)3(tpa-κ3N)]Br than phosphate buffered saline, while treatment with the 
tetracycline-Mn complex combination was superior to monotherapy, resulting in significantly 
lower mortality and morbidity rates (p < 0.049).  
Conclusions: We show that [Mn(CO)3(tpa-κ3N)]Br has in vitro and in vivo antibacterial 
activity against clinically relevant strains of S. pneumoniae and has the potential to be used in 
combination with currently available antibiotics to increase their effectiveness against MDR 
S. pneumoniae. 
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 1. Introduction 
Streptococcus pneumoniae is the main cause of community-acquired pneumonia, meningitis 
and bacteremia in children and adults1, with pneumonia remaining the leading cause of death 
in children under 5 years of age worldwide2. In addition, pneumococcal disease causes the 
most deaths among vaccine-preventable diseases, according to the World Health Organization 
(WHO)3. Although the available pneumococcal vaccines have reduced invasive 
pneumococcal disease (IPD), current vaccines only protect against a fraction of the more than 
97 circulating serotypes. Eradication of the vaccine-included serotypes has caused rapid 
serotype replacement, followed by an increase in the carriage, prevalence and disease caused 
by non-vaccine serotypes4. As a consequence of the incomplete protection against circulating 
serotypes, antibiotic therapy remains a mainstay of IPD treatment5. 
The emergence of multidrug-resistant S. pneumoniae strains worldwide compromises 
the available treatment options for IPD6-11 and imposes the need for alternatives to traditional 
anti-pneumococcal agents. Manganese-carbonyl complexes, such [Mn(CO)3(tpa-κ3N)]Br, 
have been proposed as antibacterials against Gram-negative bacteria12, 13, especially in 
combination with membrane permeabilisers like colistin14. Although their mechanism of 
action is still elusive, a combination of membrane disruption, interference of metal ion uptake 
and inhibition of respiration has been proposed15. Previous data suggests that the manganese-
coligand core of the title compound does not reach the intracellular environment in Gram-
negative bacteria, possibly due to the inability of the compound to cross the outer bacterial 
membrane16, but their antibacterial activity against Gram-positive bacteria is yet to be 
explored. 
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The aim of this study was to evaluate the in vitro and in vivo activity of manganese 
complex [Mn(CO)3(tpa-κ3N)]Br alone or in combination with commonly used antibiotics 
against multidrug-resistance strains of S. pneumoniae.  
 
2. Material and Methods 
 
2.1. Bacterial Strains, growth conditions and media 
A total of 20 human-derived clinical non-duplicate invasive and multidrug resistant S. 
pneumoniae strains were provided by the CDC Streptococcus Laboratory and were included 
in the study. Their relevant characteristics are indicated in Table S1. S. pneumoniae strains 
were grown in cation-adjusted Mueller-Hinton broth (BD, New Jersey, USA) supplemented 
with 100 U of catalase (Worthington Biochemical Corporation, New Jersey, USA) and 20 
mg/L β-NAD (Sigma-Aldrich, St. Louis, USA) at 37°C under 5% CO2 for 18-24 h. Blood 
agar plates were made from Tryptic soy agar (BD, New Jersey, USA) with the addition of 
0.5% yeast extract (BD, New Jersey, USA) and 5% defibrinated horse blood (Sanbio, Uden, 
The Netherlands). [Mn(CO)3(tpa-κ3N)]Br (USC-CN028) was synthesised according to a 
previously published procedure13.  
 
2.2. MIC and MBC determination 
Minimum inhibitory concentrations (MICs) were determined in triplicate by broth 
microdilution according to European Committee on Antimicrobial Susceptibility Testing 
(EUCAST; http://www.eucast.org) and ISO 20776-1:2006 guidelines with the exception that 
cation-adjusted Mueller-Hinton broth (BD, New Jersey, USA) was supplemented with 100 U 
of catalase (Worthington Biochemical Corporation, New Jersey, USA) instead of 5% lysed 
horse blood. The lowest concentration of compound where no turbidity was observed was 
noted as the MIC. S. pneumoniae ATCC 49619 was used as quality control.  
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Minimum bactericidal concentration (MBC) of [Mn(CO)3(tpa-κ3N)]Br was determined 
using a resazurin-based microtiter plate assay as previously described17. After adding 20 µL 
of 0.15 mg/mL resazurin (Cayman Chemical Company, Michigan, USA) solution in PBS to 
each well, plates were incubated at 37°C and the color conversion of all wells was recorded. 
The lowest well concentration of [Mn(CO)3(tpa-κ3N)]Br to remain blue was considered the 
MBC. All assays were performed in triplicate. 
 
2.3. Disc diffusion synergy test and checkerboard assays 
Synergy between [Mn(CO)3(tpa-κ3N)]Br and 11 anti-pneumococcal agents was assessed by a 
modified disk diffusion test of the EUCAST method, in that a disk of each of the anti-
pneumococcal agents was tested with and without the addition of 64 μg of [Mn(CO)3(tpa-
κ3N)]Br. A decrease in the inhibition zone diameter for the combination discs versus the discs 
alone was considered suggestive of synergy.  
To confirm the observed synergies and determine their magnitude, checkerboard 
assays were performed for three randomly selected strains (SP25, SP96 and SP30) using an 
inoculum of approximately 105 CFU/ml onto each well and a 2-fold dilution scheme. The 
fractional inhibitory concentration (FIC) for each well and the FIC index were calculated as 
previously described18. All assays were performed in triplicate. 
 
2.4. Time-kill assays 
Time-kill assays were performed in triplicate using approximately 105 CFU/mL as the starting 
inoculum for each strain and antimicrobials were added at the following final concentrations: 
[Mn(CO)3(tpa-κ3N)]Br (1 x MIC), tetracycline (1 x and 2 x MIC) and the Mn complex-
tetracycline combination (0.5 x MIC – 1 x MIC). Cultures were incubated at 37°C under 5% 
CO2 continuous agitation (225 rpm) for 24 h. At set time points of 0, 30 min, 1, 2, 4 and 24 h 
post inoculation, 100 μL samples were collected, serially diluted and cultured onto blood agar 
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plates for viable cell titer determination. Time−kill curves (CFU/ml vs time) were plotted 
using GraphPad Prism 8.2.1 software. Synergy was defined as bactericidal activity (≥2 log10 
difference in CFU/mL) of the combination compared with either agent alone, after 24 h 
incubation. Unpaired student t-tests were performed to check for significant differences. 
 
2.5. Galleria mellonella treatment assays 
S. pneumoniae inocula of approximately 0.3 OD600 (equating to ~10
8 CFU/mL) in phosphate 
buffered saline (PBS) were serially diluted in PBS and colony forming units were determined 
by plating the dilutions on blood agar and incubating for 24 h. Sixteen Galleria mellonella 
larvae (TruLarvTM, Biosystems Technology, Exeter, U.K) were infected with 105 CFU/larvae 
of each S. pneumoniae strain (SP25, SP30 and SP96) via a 10 µL injection in a left proleg as 
previously described19. Within 30 min of infection, a second injection into a right proleg was 
performed to administer the Mn complex (2.56 mg/kg in PBS), tetracycline (0.64 mg/kg), a 
combination of Mn complex and tetracycline (1.28 + 0.64 mg/kg) or PBS, respectively. 
Larvae were incubated at 37°C and scored for survival (live/dead) at 0, 24, 48, 72 and 96 h 
post inoculation.  
Melanisation scores for larvae were recorded over 96 h as an indicator of morbidity, 
based on a reversed scoring method previously published20, whereby a score of 4 indicated 
total melanisation of the larvae, 2 indicated melanin spots over the larvae, 1 indicated 
discoloration of the tail and a score of 0 indicated no melanisation.  
All assays were performed in triplicate and the data was plotted using GraphPad Prism 
8.2.1 software (San Diego, CA, USA). Analysis of survival curves was performed using the 
log rank test, with a p value of ≤ 0.05 indicating statistical significance21. Unpaired student t-
tests were performed to check for differences in bacterial counts at 24 h. 
 
3. Results and discussion 
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The antibacterial activity of [Mn(CO)3(tpa-κ3N)]Br was studied on 20 S. pneumoniae clinical 
isolates exhibiting genotypically-confirmed multidrug-resistance phenotypes (Table S1). 
[Mn(CO)3(tpa-κ3N)]Br was weak against S. pneumoniae, with MICs ranging from 64 mg/L (n 
= 11; 55%) to 128 mg/L (n = 9; 45%) (Table S1). However, this is 8- to 16-fold more active 
than previously shown against multidrug-resistant E. coli14. This enhanced activity is 
potentially due to the absence of the Gram-negative outer lipopolysaccharide membrane 
known to reduce the permeability of many antimicrobials22. The MBCs for all tested strains 
were equal to the MICs, suggesting bactericidal activity of [Mn(CO)3(tpa-κ3N)]Br. Time-kill 
assays for three randomly selected strains, SP25, SP30 and SP96, confirmed its bactericidal 
activity with total bacterial death observed within 2 h (SP25 and SP96) or 24 h (SP30) at 1x 
MIC (Figure 1a).  
The potential synergistic effect of the Mn complex with 11 other anti-pneumococcal 
agents against SP25, SP30 and SP96 was assessed by a combination disc diffusion test. All 
three strains showed a decreased diameter of inhibition zone only for the combinations of 
tetracycline, erythromycin and co-trimoxazole with the Mn complex versus these agents 
alone, suggesting synergy between these antibiotics and [Mn(CO)3(tpa-κ3N)]Br (Table S2). 
To examine strain-specific effects, we analyzed these same synergistic combinations for the 
remaining 17 multidrug-resistant S. pneumoniae strains by a combination disc diffusion test. 
Among them, eight (47.0%) exhibited decreased diameter of inhibition zone for tetracycline 
(ranging from 1 to 2 mm), 10 (58.8%) for erythromycin (ranging from 1 to 7.5 mm) and 13 
(76.5%) for co-trimoxazole (ranging from 1 to 2 mm) (Table S2). 
Checkerboard assays for SP25, SP30 and SP96 indicated that the Mn complex was 
able to increase susceptibility of tetracycline even against tetracycline-resistant strains of S. 
pneumoniae, with tetracycline MICs falling below the susceptibility breakpoint of 1 mg/L. 
Similar results showed that resistant strains were resensitized to erythromycin- and the co-
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trimoxazole-Mn complex combination (Table 1). Fractional inhibitory concentrate indexes 
were calculated and indicated that synergy was observed between co-trimoxazole and 
[Mn(CO)3(tpa-κ3N)]Br against all strains (FICI = 0.002-0.26) and against 2 out of 3 strains 
with combinations of [Mn(CO)3(tpa-κ3N)]Br with tetracycline (FICI = 0.123-0.28) and 
erythromycin (FICI = 0.28-0.31), with no additive or synergistic activity observed with the 
remaining strains (0.75-2).  
Synergy between [Mn(CO)3(tpa-κ3N)]Br and tetracycline was confirmed using time-
kill assays for the same strains, where a subinhibitory concentration of the Mn complex not 
only restored the activity of tetracycline, but was bactericidal. Bacteria were completely 
eradicated at 4 h (SP30 and SP96) and 24 h (SP25) with the combination, versus tetracycline 
alone, where an increase in bacterial numbers (107 – 108 CFU/mL) was observed at 24 h 
(Figure 1a). The combination afforded significantly greater bacterial killing compared to 
tetracycline alone against SP25, SP30 and SP96 (p = 0.04, p = 0.05 and p = 0.03 
respectively). Previous studies have also highlighted synergy between doxycycline and 
[Mn(CO)3(tpa-κ3N)]Br against E. coli by reducing the expression of tet(A)16. Therefore it is 
logical to postulate that in tet(M)-encoding S. pneumoniae, [Mn(CO)3(tpa-κ3N)]Br may 
reduce the expression of tet(M), increasing susceptibility to tetracycline. Further studies are 
needed to confirm the mechanism of synergy in S. pneumoniae and whether the activity is 
strain specific. 
To evaluate the efficacy of the tetracycline-Mn complex combination in vivo, G. 
mellonella larvae were infected with S. pneumoniae strains SP25, SP30 and SP96. Overall, 
data from in vivo experiments show a significant difference in larval mortality, between 
tetracycline monotherapy and the tetracycline-Mn complex combination (p = <0.049). With 
only PBS therapy, infections with SP25, SP30 and SP96 resulted in mortality rates of 75%, 
62.5% and 87.5%, respectively (Fig 1b), reflecting intrinsic differences in strain virulence. 
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Treatment with the tetracycline-Mn complex combination was superior to monotherapy with 
either tetracycline or the Mn complex, resulting in significantly lower mortality in infected 
larvae (20.8% vs 47.9% and 45.8% respectively). Consistent with mortality data, high 
melanisation scores indicated a strong immune response in G. mellonella infected with strains 
SP25, SP30 and SP96 (Fig. 1c), with mean scores of 47 (+/- 2.3), 63 (+/- 2.7) and 63 (+/- 1.3) 
out of a maximum of 64 for each strain, respectively. Melanisation was reduced in larvae 
treated with the tetracycline-Mn complex combination, compared with tetracycline and Mn 
complex monotherapy, with mean combined scores of 18.6 (+/- 7.2), 34.4 (+/- 9.1) and 33.7 
(+/- 6.4) respectively. Doses of [Mn(CO)3(tpa-κ3N)]Br used in this study for treatment of S. 
pneumoniae infections, were more than 70 times lower than the concentration previously 
shown to be toxic 24 h post-administration in G. mellonella14. 
In conclusion, our results show that [Mn(CO)3(tpa-κ3N)]Br used in combination with 
traditional antibiotics like tetracycline, erythromycin and co-trimoxazole, may have potential 
as antimicrobial and resistance breaker against multidrug-resistant S. pneumoniae. 
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Figure 1. (a) Time-kill curves of [Mn(CO)3(tpa-κ3N)]Br, tetracycline and combination of 
both agents (x1 MIC + 0.5 MIC) versus S. pneumoniae strains SP25, SP30 and SP96 over 24 
h. (b) Survival curves (live/dead) of Galleria mellonella over 96 h after infection with 105 
CFU/larvae of strains SP25, SP30 and SP96 and treatment with phosphate buffered saline 
(PBS), 2.56 mg/kg of [Mn(CO)3(tpa-κ3N)]Br, 0.64 mg/kg of tetracycline, and combination of 
both agents. (c) Melanisation assays in G. mellonella under the same conditions for strains 
SP25, SP30 and SP96. 
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 Table 1. Minimum inhibitory concentrations (MICs) and fractional inhibitory concentration 
index (FICI) of the antibiotics tetracycline (TET), erythromycin (ERY) and co-trimoxazole 
(SXT) alone and in combination with the Mn complex [Mn(CO)3(tpa-κ3N)]Br  against 
multidrug-resistant S. pneumoniae strains included in this study.  
Sampl
e ID 
Mn 
(mg/L
) 
TET 
+ Mn 
(mg/L
) 
 
TET 
(mg/L
) 
 
FIC
I 
ERY 
+ Mn 
(mg/L
) 
 
ERY 
(mg/L
) 
 
FIC
I 
SXT + 
Mn 
(mg/L) 
 
SXT 
(mg/L
) 
 
FIC
I 
SP25 64 0.03 0.5 0.12
3 
0.5 64 0.31 0.125 8 0.14 
SP30 128 4 8 0.75 64 64 2 0.0002
5 
0.25 0.00
2 
SP96 128 0.25 8 0.28 0.5 64 0.28 0.015 2 0.26 
 
Jo
urn
al 
Pre
-pr
oo
f
